meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 1st line (L1)
11
mRCC - L1 - PDL1 negative
1
mRCC - L1 - PDL1 positive
4
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
avelumab based treatment
avelumab plus axitinib
nivolumab based treatment
nivolumab plus cabozantinib
pembrolizumab based treatment
pembrolizumab plus axitinib
pembrolizumab plus lenvatinib
Immune checkpoint association
nivolumab plus ipilimumab
mTOR inhibitors
everolimus
lenvatinib plus everolimus
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
versus all
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs VEGF(R) inhibitor
vs sunitinib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lenvatinib in association
title
sunitinib
title
KEYNOTE-581/CLEAR (mtor), 2021 NCT02811861 metastatic/advanced RCC (mRCC) - 1st line (L1) 357/357
Pathology:
metastatic/advanced RCC (mRCC) - 1st line (L1);
metastatic/advanced RCC (mRCC) - 1st line (L1)
KEYNOTE-581/CLEAR (mtor), 2021
lenvatinib in association
1
T1
sunitinib
0
T0